Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918849 | 0.98 | MRGPRX4 (0.51) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL3915058 | 0.95 | CYP11B1 (0.51) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL5992707 | 0.86 | MRGPRX4 (0.42) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL6245912 | 0.84 | MRGPRX4 (0.52) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL27914171 | 0.84 | MAOB (0.51) | NSD2NSD3XDHMAOB | |
| SCHEMBL13223331 | 0.84 | CYP11B1 (0.51) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL11037750 | 0.83 | ALDH1A1 (0.50) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL4741497 | 0.83 | CYP11B2 (0.50) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL30580547 | 0.81 | AR (0.50) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 | |
| SCHEMBL3919607 | 0.80 | CYP11B1 (0.44) | MRGPRX4CYP11B1CYP11B2NSD2NSD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100475781-C | Androgen receptor modulators | WARNER LAMBERT CO (US) | 2009-04-08 | — | — | CN | claimed |
| CN-1918113-A | Androgen receptor modulators | WARNER LAMBERT CO (US) | 2007-02-21 | — | — | CN | claimed |
| EP-1716110-A1 | ANDROGEN RECEPTOR MODULATORS | Warner-Lambert Company LLC (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005080320-A1 | ANDROGEN RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050182132-A1 | 4-oxy-benzonitriles e.g. (1S,4S)-4-(4-Hydroxy-1-methylpentyloxy)-2-trifluoromethylbenzonitrile; acne, alopecia, and oily skin; early puberty, premenstrual syndrome, lung cancer, osteoporosis, hypogonadism, age-related muscle mass decline, hormone-dependent cancer | HU LAIN-YEN (US) | 2005-08-18 | — | — | US | claimed |
| US-7576128-B2 | Androgen receptor modulators | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576128-B2 | Androgen receptor modulators | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576128-B2 | Androgen receptor modulators | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| CN-100475781-C | Androgen receptor modulators | WARNER LAMBERT CO (US) | 2009-04-08 | — | — | CN | disclosed |
| CN-1918113-A | Androgen receptor modulators | WARNER LAMBERT CO (US) | 2007-02-21 | — | — | CN | disclosed |
| EP-1716110-A1 | ANDROGEN RECEPTOR MODULATORS | Warner-Lambert Company LLC (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080320-A1 | ANDROGEN RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182132-A1 | 4-oxy-benzonitriles e.g. (1S,4S)-4-(4-Hydroxy-1-methylpentyloxy)-2-trifluoromethylbenzonitrile; acne, alopecia, and oily skin; early puberty, premenstrual syndrome, lung cancer, osteoporosis, hypogonadism, age-related muscle mass decline, hormone-dependent cancer | HU LAIN-YEN (US) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182132-A1 | 4-oxy-benzonitriles e.g. (1S,4S)-4-(4-Hydroxy-1-methylpentyloxy)-2-trifluoromethylbenzonitrile; acne, alopecia, and oily skin; early puberty, premenstrual syndrome, lung cancer, osteoporosis, hypogonadism, age-related muscle mass decline, hormone-dependent cancer | NR5A1, AR, SHBG | MRGPRX4 1211/4885CYP11B1 29/4885CYP11B2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.